Name: Ivonescimab in EGFR-mutated non-small-cell lung cancer: Generic, brand name and therapeutic class of product
Published: 2026-09-14T15:39:06-04:00

Product information and disease description Product description Product information

Generic, brand name and therapeutic class of product

4 evidence topics · 3 sources

Manufacturer: Summit Therapeutics

“Through the License Agreement, the Company obtained the rights to develop and commercialize ivonescimab in the United States, Canada, Europe, and Japan.” (opens the source at this quote in a new tab)
“Pursuant to the terms of the License Agreement, Summit has final decision-making authority with respect to all of its commercialization activities including, but not limited to, commercial strategy, pricing and reimbursement in the Licensed Territory.” (opens the source at this quote in a new tab)

Companies and product names

Field	Quoted record
Companies	“Summit Therapeutics Inc. has a definitive partnership with Akeso, Inc.”
Product names	“Ivonescimab is known as SMT112 in Summit’s license territories”“and as AK112”

Product and Chinese trade name

“the Ivonescimab Injection (trade name: 依达方) of Akeso Inc.” (opens the source at this quote in a new tab)

Drug class

“a humanized bispecific antibody of IgG1 subtype” (opens the source at this quote in a new tab)